Loading…
← CockpitCompetitor Analysis › LEGN Legend Biotech Corp. Sponsored ADROpen in the cockpit ↗

Legend Biotech Corp. Sponsored ADRLEGNCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Develops CAR-T cell therapies for blood cancers; co-markets Carvykti for multiple myeloma with Johnson & Johnson.

Momentum laggard 18
Mkt cap
$3.12B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$53.3M
20-day average traded
Fwd P/E
34.2×
forward earnings
ROIC−WACC
-2.6 pp
WACC 7.7%
Hurdle
n/a
no reverse DCF
Next earnings
118 days
16 Mar 2027
Close · USD$16.25
1D+0.9%
1W-16.8%
1M-14.5%
3M-23.6%
6M-42.2%
YTD-25.2%
1Y-45.3%
ATR %8.5%
Beta0.64
52w lowhigh56.7% off high

What Legend Biotech Corp. Sponsored ADR does

Develops CAR-T cell therapies for blood cancers; co-markets Carvykti for multiple myeloma with Johnson & Johnson.

Janssen, Johnson & Johnson's drug unit, sells Carvykti, and the two companies share costs and profits, so Legend's income arrives as collaboration payments rather than direct drug sales. Each dose is made from the individual patient's own cells, so manufacturing capacity limits how many patients can be treated.

Products and services

  • Carvykti (multiple myeloma CAR-T)
  • Earlier-line myeloma pipeline
  • Other CAR-T programs

Customers

  • Hospitals/cancer centers (via J&J)

Where it sits in the supply chain

  • Cell therapy biopharma
  • CAR-T manufacturing
  • Oncology commercialization (with J&J)

What could go right

  • Carvykti share gains vs Abecma
  • Label expansion to earlier treatment lines

What could go wrong

  • CAR-T manufacturing/capacity bottlenecks
  • Dependence on J&J partnership economics

Moat: narrow (IP / patents, process know-how, regulatory licence). Complex CAR-T manufacturing and J&J's global commercial reach are hard to replicate quickly.

Headquarters: Somerset, New Jersey, US · Founded: 2014 · Employees: 2,900

Named competitors

Legend Biotech Corp. Sponsored ADR at a glance

Size Legend Biotech Corp. Sponsored ADR (LEGN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.12B, the 1507th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.25 on 18 Nov 2026.

Performance Over six months the shares fell 42.2%, against +1.9% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 49.7% over the last twelve months (peer median +14.8%); the operating margin is 2.8% (peer median 14.8%).

Valuation It trades at 34.2× forward earnings against a peer median of 20.7× (7th most expensive of 17).

Capital Return on invested capital runs 2.6 points below its cost of capital (7.7% WACC).

Short interest Short interest is 6.1% of the free float (30 Oct 2026).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 104LEGN 58
Six months, rebased to 100: Legend Biotech Corp. Sponsored ADR against the median of its 20 peers (local-currency closes).

Legend Biotech Corp. Sponsored ADR financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.36B$1.03B$628M$285M$117M
Revenue growth—+64%+120%+144%—
Gross profit$726M$593M$369M$120M$33.2M
EBITDA$88.4M-$108M-$286M-$421M-$439M
Net income-$318,707-$298M-$177M-$518M-$446M
Free cash flow-$336M-$168M-$210M-$503M-$235M
Capital expenditure$88.3M$67.6M$69.0M$121M$37.0M
Total debt$167M$414M$351M$329M$285M

Quarterly statements and history in the cockpit →

Legend Biotech Corp. Sponsored ADR competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%688266ACAD6005352696600511VCEL0027730867NEULANDLABVKTX000739PPLPHARMA2096VRDNAMLX600380688180ARQTACUTAASLEGN6-month return →1-month return →
Up and to the right = strong over both horizons. Legend Biotech Corp. Sponsored ADR is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×688266ACAD6005352696600511VCEL0867NEULANDLAB000739PPLPHARMA600380ARQTACUTAASLEGNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Legend Biotech Corp. Sponsored ADR is the large dot.

Legend Biotech Corp. Sponsored ADR competitors and peer comparison

Head to head with its named competitors (LEGN vs BMY vs JNJ vs GILD)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Legend Biotech Corp. Sponsored ADR LEGN$3.12B-42%+50%3%34.2×n/a
Bristol Myers Squibb BMY$122B+3%+4%33%9.2×-13.1%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Gilead Sciences GILD$210B+30%+7%38%19.9×-2.4%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%11.8×-1.1%
Autolus Therapeutics Plc Sponsored ADR AUTLn/a-35%n/an/an/an/a

How Legend Biotech Corp. Sponsored ADR compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Legend Biotech Corp. Sponsored ADR against its 20 peers (data as of 18 Nov 2026)
MeasureLEGNPeer medianRank in peer set
1-month return-14.5%-0.1%4th lowest of 21
6-month return-42.2%+1.9%lowest of 21
Distance from 52-week high-56.7%-19.4%lowest of 21
Revenue growth (TTM)+49.7%+14.8%5th highest of 20
Operating margin2.8%14.8%3rd lowest of 19
Forward P/E34.2×20.7×7th most expensive of 17
ROIC minus cost of capital-2.6 pp+7.9 pp4th lowest of 17
EV / EBITDA27.6×30.7×5th cheapest of 10
Net debt / EBITDA-7.8×-0.8×least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a

Questions

Who are Legend Biotech Corp. Sponsored ADR's main competitors?
Named competitors: Bristol Myers Squibb (Abecma) (BMY), Johnson & Johnson (JNJ), Arcellx (private or unlisted), Gilead Sciences (GILD), Pfizer (PFE), Regeneron Pharmaceuticals (REGN). The cockpit's measured peer set (industry) also includes Suzhou Zelgen Biopharmaceuticals (688266.SS), ACADIA Pharmaceuticals (ACAD), Tasly Pharmaceutical (600535.SS), Shanghai Henlius Biotech (2696.HK), China National Medicines (600511.SS), Vericel (VCEL).
Is Legend Biotech Corp. Sponsored ADR expensive compared with its peers?
On forward p/e it trades at 34.2× against a peer median of 20.7×, 7th most expensive of 17 in its peer set.
How has Legend Biotech Corp. Sponsored ADR stock performed?
Over six months to 18 Nov 2026 the shares returned -42.2% against +1.9% for the median peer; over one year -45.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.